5.1.2e

5.1.2e

5.1.2e

Declaration of the End of Trial Form (cf. Section 4.2.1 of the *Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial*[1])

NOTIFICATION OF THE END OF A CLINICAL TRIAL OF A MEDICINE FOR HUMAN USE TO THE COMPETENT AUTHORITY AND THE ETHICS COMMITTEE

For official use

Date of receipt :	Competent authority registration number : Ethics committee registration number:

To be filled in by the applicant

A MEMBER STATE IN WHICH THE DECLARATION IS BEING MADE : The NETHERLANDS

B TRIAL IDENTIFICATION

B.1 EudraCT number : **2020-003124-16**
B.2 Sponsor's protocol code number: **KH176-204: KHENERGYC study**
B.3 Full title of the trial : ***A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease***

C APPLICANT IDENTIFICATION (please tick the appropriate box)

C.1	**DECLARATION FOR THE COMPETENT AUTHORITY**	☐
C.1.1	Sponsor	X
C.1.2	Legal representative of the sponsor	☐
C.1.3	Person or organisation authorised by the sponsor to make the application.	☐
C.1.4	**Complete below**:	
C.1.4.1	Organisation : Khondrion B.V.	
C.1.4.2	Name of person to contact : [redacted]	
C.1.4.3	Address : Novio Tech Campus Gebouw M, postbus nummer C Transistorweg 5 C, 6534 AT Nijmegen	
C.1.4.4	Telephone number : +31 (0)[redacted]	
C.1.4.5	Fax number : N/A	
C.1.4.6	E-mail: [redacted]@khondrion.com	

C.2	**DECLARATION FOR THE ETHICS COMMITTEE**	☐
C.2.1	Sponsor	☐
C.2.2	Legal representative of the sponsor	☐
C.2.3	Person or organisation authorised by the sponsor to make the application.	☐
C.2.4	Investigator in charge of the application if applicable[2]:	
	• Co-ordinating investigator (for multicentre trial):	☐
	• Principal investigator (for single centre trial):	☐
C.2.5	**Complete below** :	
C.2.5.1	Organisation:	
C.2.5.2	Name :	
C.2.5.3	Address :	
C.2.5.4	Telephone number :	
C.2.5.5	Fax number :	
C.2.5.6	E-mail :	

1 OJ, C82, 30.3.2010, p. 1; hereinafter referred to as 'detailed guidance CT-1'.
2 According to national legislation.

51.1c
51.1c

D END OF TRIAL

D.1 Date of the end of the trial in this Member State ? [3]	yes **X** no ☐
D.1.1. (YYYY/MM/DD): 2024-12-20	

D.2 Date of the end of the complete trial in all countries concerned by the trial? [3]	yes **X** no ☐
D.2.1 (YYYY/MM/DD): 2024-12-20	

D.3 Is it an early termination? [4]	yes **X** no ☐

D.3.1 If yes, give date (YYYY/MM/DD): 2024-12-20

D.3.2 Briefly describe in an annex (free text):

D.3.2.1 The justification for early termination of the trial;

The aim of the study was to include 24 pediatric patients, with the first recruitments early 2021. After almost four years, it appears that the strict inclusion criteria and the study procedures that were experienced by the patients as intensive and very burdensome have hampered the feasibility of the study. At the Radboudumc location, it was difficult to find newly diagnosed patients, as all known patients had already been assessed for potential eligibility. In addition, patients and their families indicated that the study procedures were experienced as very burdensome. This feedback will likely have been shared within the close-knit PMD community, which may have had negative consequences for further recruitment.

[redacted]

This study was not terminated early for safety concerns.

D.3.2.2 Number of patients still receiving treatment at time of early termination in the MS concerned by the declaration and their proposed management; *Study KH176-204 is a single site trial (Investigational site the Netherlands: Radboudumc. At the trial site in The Netherlands, 16* [redacted] *PMD patients known to the site were eligible for screening of whom 4 were screen failures due to not meeting the GMFM-88 ≤96% criterion. Of the 12 eligible patients, 6 were included in the initial PK phase of the trial (n=3 aged 12 to <18 years; n=3 aged 6 to <12 years) and all 12 were included in the main 6-month randomised controlled trial. 4/12 patients (33.3%) were withdrawn from the study. Reasons for withdrawal were: 1 x protocol violation, 1 x adverse event, 1 x withdrawal of consent and 1 x treatment non-compliance. There were 4 patients in each age subset who completed the trial. At the time of the termination no patients were receiving treatment with IP. Last patient Last Visit: 15-07-2022. The investigational site (Radboudumc) was formally closed 20-12-2024.*

D.3.2.3 The consequences of early termination for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product. *An abbreviated Clinical Study Report (CSR) will be generated. This CSR will contain (at least) a descriptive analysis of the collected data and a full presentation and discussion of all safety data.*

---

[3] In case of a multi-country trial, if the national and global end of trial dates are different in a given Member State, the sponsor shall submit this form two times :

1) At the end of the trial in the individual Member State, section D1.1. shall be completed and submitted to the respective National Competent Authority.

2) At the global end of the trial, the sponsor shall complete section D.2.1. with the global trial end date and the completed form shall be submitted to all participating Member States in order to allow the sponsor to prepare the trial result summary within the 12-months (or 6-months in case of paediatric trials) timeframe.

If the national and global end dates coincide in a concerned Member State, the form shall be submitted only once to the National Competent Authority of this Member State with both sections D1.1. and D2.1 complete.

[4] Cf. Section 4.2. of the detailed guidance CT-1.

E SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

51.2e

E.1	I hereby confirm that/confirm on behalf of the sponsor that (delete which is not applicable): • The above information given on this declaration is correct; and • That the clinical trial summary report will be submitted within the applicable deadlines in accordance with the applicable guidance by the Commission.[5]

E.2	**APPLICAN[redacted]ETENT AUTHORITY** (as stated in C.1)	☐
E.2.1	Date : 16-0[redacted]	
E.2.2	Signature :	
E.2.3	Print name:	

E.3	**APPLICANT TO THE ETHICS COMMITTEE** (as stated in C.2) **:**	☐
E.3.1	Date :	
E.3.2	Signature :	
E.3.3	Print name:	

[5] Section 4.3. of the detailed guidance CT-1.